TY - JOUR
T1 - Effects of propofol on Ca2+ regulation by malignant hyperthermia- susceptible muscle membranes
AU - Fruen, B. R.
AU - Mickelson, J. R.
AU - Roghair, T. J.
AU - Litterer, L. A.
AU - Louis, C. F.
PY - 1995
Y1 - 1995
N2 - Background: The effects of inhalation anesthetics on Ca2+ regulation in malignant hyperthermia-susceptible skeletal muscle are considered to be responsible for triggering malignant hyperthermia. The intravenous anesthetic propofol does not trigger malignant hyperthermia in susceptible patients or experimental animals, suggesting that there are important differences between the effects of propofol and the effects of inhalation anesthetics on Ca2+ regulation in malignant hyperthermia-susceptible muscle. Understanding these differences may help to clarify the mechanisms responsible for triggering malignant hyperthermia. Methods: To investigate the effects of propofol on Ca2+ regulation by malignant hyperthermia susceptible skeletal muscle, we determined its effects on the membrane channels and pumps that control myoplasmic Ca2+ concentrations: the sarcoplasmic reticulum ryanodine receptor, the transverse tubule dihydropyridine receptor, and the sarcoplasmic reticulum Ca2+-adenosine triphosphatase (Ca2+-ATPase). Terminal cisternae-derived sarcoplasmic reticulum vesicles enriched in the junctional proteins of the sarcoplasmic reticulum and the transverse tubule membranes were isolated from the muscle of malignant hyperthermia-susceptible and normal pigs. Ca2+ flux, Ca2+-ATPase, and ligand binding measurements on these isolated vesicle preparations were performed in the presence of varying propofol concentrations. Results: Propofol (10-500 μM) had no effect on ryanodine receptor-mediated Ca2+ efflux from muscle membrane vesicles. Propofol (1-100 μM) also had no effect on sarcoplasmic reticulum vesicle [3H]ryanodine binding, whereas higher concentrations (200-300 μM) slightly inhibited [3H}ryanodine binding. Binding of the dihydropyridine receptor Ca2+ channel blocker [3H]PN200-110 to these preparations was inhibited by propofol (10-300 μM). Ca2+-ATPase activity was stimulated by 10-100 μM propofol but was inhibited by higher concentrations. In all cases, the effects of propofol on malignant hyperthermia-susceptible and normal membrane preparations were similar. Conclusions: In contrast to malignant hyperthermia-triggering inhalation anesthetics, propofol does not stimulate malignant hyperthermia-susceptible or normal ryanodine receptor channel activity, even at > 100 times clinical concentrations. Effects on dihydropyridine receptor and Ca2+-ATPase function, however, are similar to the effects of inhalation anesthetics and require much lower concentrations of propofol. These findings, demonstrating that propofol does not activate ryanodine receptor Ca2+ channels, suggest a plausible explanation for why propofol does not trigger malignant hyperthermia in susceptible persons.
AB - Background: The effects of inhalation anesthetics on Ca2+ regulation in malignant hyperthermia-susceptible skeletal muscle are considered to be responsible for triggering malignant hyperthermia. The intravenous anesthetic propofol does not trigger malignant hyperthermia in susceptible patients or experimental animals, suggesting that there are important differences between the effects of propofol and the effects of inhalation anesthetics on Ca2+ regulation in malignant hyperthermia-susceptible muscle. Understanding these differences may help to clarify the mechanisms responsible for triggering malignant hyperthermia. Methods: To investigate the effects of propofol on Ca2+ regulation by malignant hyperthermia susceptible skeletal muscle, we determined its effects on the membrane channels and pumps that control myoplasmic Ca2+ concentrations: the sarcoplasmic reticulum ryanodine receptor, the transverse tubule dihydropyridine receptor, and the sarcoplasmic reticulum Ca2+-adenosine triphosphatase (Ca2+-ATPase). Terminal cisternae-derived sarcoplasmic reticulum vesicles enriched in the junctional proteins of the sarcoplasmic reticulum and the transverse tubule membranes were isolated from the muscle of malignant hyperthermia-susceptible and normal pigs. Ca2+ flux, Ca2+-ATPase, and ligand binding measurements on these isolated vesicle preparations were performed in the presence of varying propofol concentrations. Results: Propofol (10-500 μM) had no effect on ryanodine receptor-mediated Ca2+ efflux from muscle membrane vesicles. Propofol (1-100 μM) also had no effect on sarcoplasmic reticulum vesicle [3H]ryanodine binding, whereas higher concentrations (200-300 μM) slightly inhibited [3H}ryanodine binding. Binding of the dihydropyridine receptor Ca2+ channel blocker [3H]PN200-110 to these preparations was inhibited by propofol (10-300 μM). Ca2+-ATPase activity was stimulated by 10-100 μM propofol but was inhibited by higher concentrations. In all cases, the effects of propofol on malignant hyperthermia-susceptible and normal membrane preparations were similar. Conclusions: In contrast to malignant hyperthermia-triggering inhalation anesthetics, propofol does not stimulate malignant hyperthermia-susceptible or normal ryanodine receptor channel activity, even at > 100 times clinical concentrations. Effects on dihydropyridine receptor and Ca2+-ATPase function, however, are similar to the effects of inhalation anesthetics and require much lower concentrations of propofol. These findings, demonstrating that propofol does not activate ryanodine receptor Ca2+ channels, suggest a plausible explanation for why propofol does not trigger malignant hyperthermia in susceptible persons.
KW - Anesthetics, intravenous: propofol
KW - Hyperthermia: malignant
KW - Muscle, skeletal: calcium channels; sarcoplasmic reticulum
KW - Receptors: ryanodine
UR - http://www.scopus.com/inward/record.url?scp=0028989490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028989490&partnerID=8YFLogxK
U2 - 10.1097/00000542-199505000-00023
DO - 10.1097/00000542-199505000-00023
M3 - Article
C2 - 7741303
AN - SCOPUS:0028989490
SN - 0003-3022
VL - 82
SP - 1274
EP - 1282
JO - Anesthesiology
JF - Anesthesiology
IS - 5
ER -